ChemoMetec A/S CHEMM
OMXCOP · Denmark · Health Technology
DKK 519.00-4.00 (-0.76%)
Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
ChemoMetec AS (STU:CHY) posted record DKK511 million revenue with a 55% EBITDA margin, but management's conservative FY26/27 outlook and rising CapEx keep investors guessing.
16 September 2026ANNOUNCEMENT NO. 315 Major shareholder announcement - BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock, Inc., on 14 September 2026, increased its total holding in ChemoMetec A/S to 15.00%, and that the holding thus has reached the 15 per cent limit in Section 38 of the Capital Markets Act. Additional information Martin Helbo Behrens, CEOTel.: (+45) 81 10 06 80 Phillip Massie
ANNOUNCEMENT NO. 31310 September 2026 Annual Report 2025/26 (1 July 2025 - 30 June 2026) Positioning ChemoMetec for future growth Despite changes and uncertainty affecting ChemoMetec's markets, revenue grew by 3% to DKK 511.1 million in 2025/26 whilst EBITDA grew from DKK 258.0 million to DKK 281.3 million. The growth was driven by increased sales of new instruments and services, with sales of XcytoMatic instruments rising from DKK 27.7 million to DKK 61.8 million. Towards the end of the financi
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.